View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

  • Notice Summary
    UK-Southampton: 19/31 Gastrointestinal Side Effects in Cancer Immune Checkpoint Therapy
    GB003ZM291121
    National Insttitute for Health Research
    27 March 2019
    31 July 2019
    Contract Notice - Other
  • Notice Abstract

    The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic: 19/31 Gastrointestinal side effects in cancer immune checkpoint therapy Rationale: The immune checkpoint inhibitor drugs (ipilimumab, nivolumab and pembrolizumab) are indicated (and recommended) for a number of malignancies including advanced melanoma, non-small-cell lung cancer and advanced renal cell carcinoma. While these drugs can provide significant survival advantage over existing treatments they can and do cause a range of immune related adverse effects including diarrhoea and colitis which can be potentially fatal. How best to manage these treatment related adverse events is uncertain with current guidance generally based on clinical experience of the use of these agents in clinical studies, and accounting for what is known of their potential mechanisms of toxicity. Treatment with steroids is the mainstay of management but the use of infliximab, another expensive toxic monoclonal antibody, is also indicated. The optimum strategy for use of these, and other, agents is however unclear and prospective trials are required to provide evidence to aid decision making for clinicians and patients which balances quality of life, effectiveness of the primary treatment as well as resource use.

  • Notice Details

    CONTRACT NOTICE – NATIONAL

    SERVICES

    1 Authority Details

    1.1

    Authority Name and Address


    National Insttitute for Health Research

    N/A

    Southampton


    UK

    N/A

    N/A


    N/A

    1.2

    Address from which documentation may be obtained

    As in 1.1

    1.3

    Completed documents must be returned to:

    As in 1.1

    2 Contract Details

    2.1

    Title

    19/31 Gastrointestinal Side Effects in Cancer Immune Checkpoint Therapy

    2.2

    Description of the goods or services required

    The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic:

    19/31 Gastrointestinal side effects in cancer immune checkpoint therapy

    Rationale:

    The immune checkpoint inhibitor drugs (ipilimumab, nivolumab and pembrolizumab) are indicated

    (and recommended) for a number of malignancies including advanced melanoma, non-small-cell

    lung cancer and advanced renal cell carcinoma.

    While these drugs can provide significant survival advantage over existing treatments they can and

    do cause a range of immune related adverse effects including diarrhoea and colitis which can be

    potentially fatal. How best to manage these treatment related adverse events is uncertain with

    current guidance generally based on clinical experience of the use of these agents in clinical

    studies, and accounting for what is known of their potential mechanisms of toxicity.

    Treatment with steroids is the mainstay of management but the use of infliximab, another expensive

    toxic monoclonal antibody, is also indicated. The optimum strategy for use of these, and other,

    agents is however unclear and prospective trials are required to provide evidence to aid decision

    making for clinicians and patients which balances quality of life, effectiveness of the primary

    treatment as well as resource use.

    2.3

    Notice Coding and Classification

    2.4

    Total quantity or scope of tender

    3 Conditions for Participation

    3.1

    Minimum standards and qualification required

    4 Administrative Information

    4.1

    Type of Procedure

    The procedure type is unknown.

    4.2

    Reference number attributed to the notice by the contracting authority

    19/31

    4.3

    Time Limits

       31-07-2019  Time 13:00

    4.5

    Language or languages in which tenders or requests to participate can be drawn up

    EN 

    4.6

    Tender Submission Postbox

    5 Other Information

    5.1

    Additional Information

    Please visit the following portal to view this notice:

    https://www.nihr.ac.uk/funding-and-support/funding-opportunities/1931-gastrointestinal-side-effects-in-cancer-immune-checkpoint-therapy/10559

    The deadline for applications is 1pm, 31 July 2019.

    (MT Ref:291121)

    5.2

    Additional Documentation

    5.3

    Publication date of this notice

     27-03-2019